FACC

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Wednesday, March 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

BRAINBox Solutions to Present Updated Data at Three Leading Conferences from HeadSMART II and NIH-funded Geriatrics Clinical Trials of BRAINBox TBI Concussion Test

Retrieved on: 
Monday, March 4, 2024
Doctor of Philosophy, Concussion, Emergency, TBI, Poster, Diagnosis, Bangladesh Technical Education Board, School, Alzheimer's disease, Algorithm, Geriatrics, NIH, Emergency medicine, FESC, FACC, Brainbox, Trauma, FACEP, Traumatic brain injury, ATE, Conference, Prognosis, Biomarker, Clinical trial, Serum, Medical school, Blood, Risk, Patient, Baylor College of Medicine, Update, Parkinson's disease, Medical device

RICHMOND, Va., March 4, 2024 /PRNewswire/ -- BRAINBox Solutions today announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded clinical trial in geriatric patients of its BRAINBox TBI™ concussion diagnostic and prognostic test.  Concussion is also known as ATE (Acute Traumatic Encephalopathy) or mTBI (mild traumatic brain injury).

Key Points: 
  • The presentation title is, "Biomarker Profiles Distinguish Geriatric Acute TBI from Dementias:  Results from the HeadSMARTII Geriatric Feasibility Study.
  • "  The poster title is: "Biomarker Profiles Distinguish Geriatric TBI from Dementias:  Results From the HeadSMART Geriatric Feasibility Study."
  • "These presentations highlight the breadth of clinical data being assembled to evaluate the diagnostic and prognostic potential of the BRAINBox TBI test across a spectrum of age groups.
  • "These two trials have made substantial progress, as enrollment in both is expanding and, in the case of HeadSMART II, almost completed," said Donna Edmonds, BRAINBox Solutions' CEO.

EISENHOWER HEALTH EARNS NATIONAL RECOGNITION WITH HeartCARE CENTER DESIGNATION

Retrieved on: 
Wednesday, February 28, 2024
TAVR, Hospital, BSN, Aortic stenosis, Resuscitation, Registry, RN, Electrophysiology, MBA, Cardiology, Heart failure, NCDR, American College, Patient, MPH, FACC, Disease, Heart, ACC, Coachella Valley, Accreditation, PCI, Nursing

RANCHO MIRAGE, Calif., Feb. 28, 2024 /PRNewswire/ -- The American College of Cardiology has recognized Eisenhower Health for its demonstrated commitment to comprehensive, high-quality culture and cardiovascular care. Eisenhower Health was awarded the HeartCARE Center National Distinction of Excellence based on meeting accreditation criteria, and through their ongoing performance registry reporting.

Key Points: 
  • Eisenhower Health was awarded the HeartCARE Center National Distinction of Excellence based on meeting accreditation criteria, and through their ongoing performance registry reporting.
  • "We are proud to be the Coachella Valley's only heart program to earn the HeartCARE Center distinction.
  • "ACC Accreditation Services is proud to award Eisenhower Health with the HeartCARE Center designation."
  • Eisenhower Health has proven to be a forward-thinking institution with goals to advance the cause of sustainable quality improvement.

Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas

Retrieved on: 
Tuesday, February 27, 2024
Senior, Research, Morehouse School of Medicine, Medical school, Education, MHS, Vanderbilt University Medical Center, University, History, Internal medicine, Texas Southern University, Principal, Professor, Health informatics, MBA, FACP, FACC, Partnership, Informatics, RCMI, Drug discovery, Yale School of Medicine, Yale University, MPH, Clinical trial, Health equity, Trust, Face, Innovation, Public health, Dean (education), Patient, Yale school, Science, Nursing

NEW HAVEN, Conn., Feb. 26, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt University Medical Center, is a partnership bringing clinical trial sites closer to the community to further equity and access for diverse populations. Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities. The partnerships include:

Key Points: 
  • Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities.
  • The program works to increase awareness of clinical trials, address misinformation and historical mistrust, while ensuring the trial is easily accessible.
  • The EQBMED partnership meets sites where they are, building on their strengths and capabilities to become sustainable within the clinical trial ecosystem.
  • "EQBMED is making real progress towards equitable access to clinical trials and enhancing these sites with needed resources."

Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas

Retrieved on: 
Monday, February 26, 2024
Senior, Research, Morehouse School of Medicine, Medical school, Education, MHS, Vanderbilt University Medical Center, University, History, Internal medicine, Texas Southern University, Principal, Professor, Health informatics, MBA, FACP, FACC, Partnership, Informatics, RCMI, Drug discovery, Yale School of Medicine, Yale University, MPH, Clinical trial, Health equity, Trust, Face, Innovation, Public health, Dean (education), Patient, Yale school, Science, Nursing

NEW HAVEN, Conn., Feb. 26, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt University Medical Center, is a partnership bringing clinical trial sites closer to the community to further equity and access for diverse populations. Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities. The partnerships include:

Key Points: 
  • Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities.
  • The program works to increase awareness of clinical trials, address misinformation and historical mistrust, while ensuring the trial is easily accessible.
  • The EQBMED partnership meets sites where they are, building on their strengths and capabilities to become sustainable within the clinical trial ecosystem.
  • "EQBMED is making real progress towards equitable access to clinical trials and enhancing these sites with needed resources."

Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas

Retrieved on: 
Monday, February 26, 2024
Senior, Research, Morehouse School of Medicine, Medical school, Education, MHS, Vanderbilt University Medical Center, University, History, Internal medicine, Texas Southern University, Principal, Professor, Health informatics, MBA, FACP, FACC, Partnership, Informatics, RCMI, Drug discovery, Yale School of Medicine, Yale University, MPH, Clinical trial, Health equity, Trust, Face, Innovation, Public health, Dean (education), Patient, Yale school, Science, Nursing

NEW HAVEN, Conn., Feb. 26, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt University Medical Center, is a partnership bringing clinical trial sites closer to the community to further equity and access for diverse populations. Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities. The partnerships include:

Key Points: 
  • Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities.
  • The program works to increase awareness of clinical trials, address misinformation and historical mistrust, while ensuring the trial is easily accessible.
  • The EQBMED partnership meets sites where they are, building on their strengths and capabilities to become sustainable within the clinical trial ecosystem.
  • "EQBMED is making real progress towards equitable access to clinical trials and enhancing these sites with needed resources."

PUER Joins Campden Wealth As a Corporate Partner to Provide Multigenerational Health Resources

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Education, Cholesterol, Physician, Molecular medicine, FAHA, Drug development, System, Health, Therapy, UHNW, Genome, FACC, Genomics, Trial of the century, Management

ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.

Key Points: 
  • ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.
  • PUER is joining the Campden Wealth community as one of Campden Wealth's select corporate partners for 2024.
  • PUER offers a high-touch, high-science, multigenerational concierge program with the most comprehensive health planning for families.
  • A centennial time horizon aims to complement multigenerational family education and resources facilitated by Campden Wealth.

DynaMed® Named 2024 Best in KLAS for Clinical Decision Support

Retrieved on: 
Wednesday, February 7, 2024
Software, FAHA, Research, Feedback, FACP, EBSCO, FACC, Information services, Trust, Human, Nursing

IPSWICH, Mass., Feb. 7, 2024 /PRNewswire-PRWeb/ -- DynaMed®, a Clinical Decisions resource from EBSCO Information Services (EBSCO), is named the top performing point-of-care clinical reference tool in the 2024 Best in KLAS Software and Services report. KLAS, a research firm that specializes in monitoring and reporting the performance of health care vendors, ranked DynaMed the number one clinical decision support point-of-care reference tool among health care organizations. This is the third year that DynaMed has been ranked number one clinical decision support reference tool, and the fifth year the tool has been included in the Best in KLAS: Software and Services report.

Key Points: 
  • IPSWICH, Mass., Feb. 7, 2024 /PRNewswire-PRWeb/ -- DynaMed ®, a Clinical Decisions resource from EBSCO Information Services (EBSCO), is named the top performing point-of-care clinical reference tool in the 2024 Best in KLAS Software and Services report .
  • KLAS , a research firm that specializes in monitoring and reporting the performance of health care vendors, ranked DynaMed the number one clinical decision support point-of-care reference tool among health care organizations.
  • This is the third year that DynaMed has been ranked number one clinical decision support reference tool, and the fifth year the tool has been included in the Best in KLAS: Software and Services report.
  • The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation.

Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Collaboration, Regurgitation, GI, IND, Patient, Gastroparesis, FDA, Food, D2, PPI, Gastroesophageal reflux disease, FACC, Disease, Heartburn, GERD, Pharmaceutical industry

Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.

Key Points: 
  • Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.
  • In October 2021, Renexxion and Dr. Falk Pharma announced an exclusive Licensing and Collaboration Agreement to advance naronapride initially for gastroparesis in Greater Europe (including UK), Russia, Central Asian Republics, and certain Australasian countries.
  • Today, Renexxion is pleased to confirm that Dr. Falk Pharma will also advance naronapride for PPI-non-responsive symptomatic GERD in these regions.
  • This is a welcomed addition to our pipeline which includes naronapride for gastroparesis.”
    “We are very pleased that our European partner, Dr. Falk Pharma, chose PPI-nrsGERD as its next indication for development for naronapride in their territories.

New Book Introduces Plan That Works Like Weight-Loss Drug Without a Prescription

Retrieved on: 
Wednesday, February 7, 2024
Lifestyle, Health, General Health, Food, Beverage, Entertainment, Books, Research, Retail, Fitness & Nutrition, Consumer, Science, Plant, Weight loss, Grain boundary strengthening, Meal, Prediabetes, Vegetable, MyPlate, Interview, Molina Healthcare, Overweight, Cheese, DIET, Coconut oil, Diabetes, Child, Arthritis, Salmon, Obesity, Hypertension, The New York Times, FACC, POWER, Ethics, Burns, Woman, Dietary supplement

Dr. Barnard shows that certain foods actually cause weight loss, like a weight-loss medication without a prescription.

Key Points: 
  • Dr. Barnard shows that certain foods actually cause weight loss, like a weight-loss medication without a prescription.
  • The Power Foods Diet , by Balance Publishing, is available for preorder now and will be on bookshelves everywhere March 26.
  • “In reality, the best solution for reaching and maintaining a healthy weight is a low-fat plant-based diet that excludes animal products.
  • Two women who each lost 100 pounds following the plan are featured in the book.